TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.

The first treatment specifically for metastatic non-small cell lung cancer (mNSCLC) with an abnormality in the MET gene called MET exon 14 skipping (METex14).

Approved Use

TABRECTA is a prescription medicine used to treat adults with a kind of lung cancer called non-small cell lung cancer (NSCLC) that:

  • has spread to other parts of the body or cannot be removed by surgery (metastatic), and
  • whose tumors have an abnormal mesenchymal-epithelial transition (MET) gene


Proven clinical trial results

In a clinical trial, TABRECTA was studied in different groups of people with MET exon 14 skipping: those taking TABRECTA as their first treatment and those previously treated before taking TABRECTA.

  • The overall response rate measures the size or number of tumors people have. This includes:
    • people whose tumors became smaller or fewer in number (which is called a partial response), and
    • people whose tumors disappeared completely (which is called a complete response). A complete response is not the same thing as a cure.

Duration of response is the length of time that a tumor continues to respond to treatment without the cancer growing or spreading.

Download for details: TABRECTA